Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Raltegravir Potassium

FDA-approved product (tablet, oral), marketed as Isentress, Isentress Hd, Raltegravir Potassium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Raltegravir Potassium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Integrase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AJ01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Raltegravir Potassium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-9.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Raltegravir Potassium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients

    NCT01201239 · start 2010-09

    Registered record
    Registry ID
    NCT01201239
    Conditions
    HIV
    Interventions
    raltegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2010-09
    Completion
    2012-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventionraltegravir
    PhasePhase 4
    Registry statusUnknown

  • A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

    NCT01101893 · start 2010-04

    Registered record
    Registry ID
    NCT01101893
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    Raltegravir; GSK2248761; GSK2248761 + Raltegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-06
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionRaltegravir; GSK2248761; GSK2248761 + Raltegravir
    PhasePhase 1
    Registry statusCompleted

  • A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen

    NCT00931463 · start 2009-09

    Registered record
    Registry ID
    NCT00931463
    Conditions
    HIV Infections
    Interventions
    raltegravir; 2N(t)RTI; Ritonavir-boosted lopinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-08
    Enrolment
    558

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionraltegravir; 2N(t)RTI; Ritonavir-boosted lopinavir
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients

    NCT00943540 · start 2009-07

    Registered record
    Registry ID
    NCT00943540
    Conditions
    HIV Infection; HIV Infections
    Interventions
    raltegravir QD; atazanavir; lamivudine (or emtricitabine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    2011-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; HIV Infections
    Interventionraltegravir QD; atazanavir; lamivudine (or emtricitabine)
    PhasePhase 2
    Registry statusCompleted

  • Pilot Study of a Raltegravir Based NRTI Sparing Regimen

    NCT00814879 · start 2009-05

    Registered record
    Registry ID
    NCT00814879
    Conditions
    Acquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV Infections
    Interventions
    Raltegravir; Atazanavir; Standard treatment regimen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-05
    Completion
    2013-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV Infections
    InterventionRaltegravir; Atazanavir; Standard treatment regimen
    PhaseNot applicable
    Registry statusCompleted

  • A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

    NCT00870363 · start 2009-04

    Registered record
    Registry ID
    NCT00870363
    Conditions
    HIV Infections
    Interventions
    maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2013-04
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionmaraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor); efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]
    PhasePhase 4
    Registry statusCompleted

  • Buprenorphine/Raltegravir Pharmacokinetic Interaction Study

    NCT00858962 · start 2009-03

    Registered record
    Registry ID
    NCT00858962
    Conditions
    HIV Infection; HIV Infections
    Interventions
    Raltegravir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-03
    Completion
    2009-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; HIV Infections
    InterventionRaltegravir
    PhaseNot applicable
    Registry statusCompleted

  • Drug Interaction Study Between Raltegravir And UK-453,061

    NCT00784420 · start 2008-09

    Registered record
    Registry ID
    NCT00784420
    Conditions
    Healthy Volunteers
    Interventions
    UK-453,061; UK-453,061; Raltegravir; Raltegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionUK-453,061; UK-453,061; Raltegravir; Raltegravir
    PhasePhase 1
    Registry statusCompleted

  • Kaletra in Combination With Antiretroviral Agents

    NCT01076179 · start 2008-09

    Registered record
    Registry ID
    NCT01076179
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-09
    Completion
    2016-01
    Enrolment
    502

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women

    NCT00774683 · start 2008-08

    Registered record
    Registry ID
    NCT00774683
    Conditions
    HIV; AIDS
    Interventions
    Raltegravir (Isentress®)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-08
    Completion
    2009-09
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; AIDS
    InterventionRaltegravir (Isentress®)
    PhaseNot recorded
    Registry statusCompleted

  • Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

    NCT00708162 · start 2008-07

    Registered record
    Registry ID
    NCT00708162
    Conditions
    HIV Infection
    Interventions
    Elvitegravir; Raltegravir; EVG placebo; RAL placebo; Background regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2015-04
    Enrolment
    724

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionElvitegravir; Raltegravir; EVG placebo; RAL placebo +1 more
    PhasePhase 3
    Registry statusCompleted

  • Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

    NCT00738569 · start 2008-07

    Registered record
    Registry ID
    NCT00738569
    Conditions
    HIV
    Interventions
    Raltegravir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-07
    Completion
    2011-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionRaltegravir
    PhaseNot applicable
    Registry statusCompleted

  • HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

    NCT00709397 · start 2008-06

    Registered record
    Registry ID
    NCT00709397
    Conditions
    HIV-1 Infection
    Interventions
    blood drawing
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2008-06
    Completion
    2009-12
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    Interventionblood drawing
    PhaseNot recorded
    Registry statusTerminated

  • Observational Data Analysis in EuroSIDA (MK-0518-058)

    NCT01078233 · start 2008-05-05

    Registered record
    Registry ID
    NCT01078233
    Conditions
    HIV-1 Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-05-05
    Completion
    2014-03-06
    Enrolment
    6,617

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

    NCT00751153 · start 2008-03

    Registered record
    Registry ID
    NCT00751153
    Conditions
    HIV Infections
    Interventions
    Raltegravir and Atazanavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-03
    Completion
    2009-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRaltegravir and Atazanavir
    PhasePhase 4
    Registry statusUnknown